UBS analyst Marc Goodman lowered his price target on Gilead Sciences (NASDAQ: GILD) to $118.00 (from $130.00) following Q1 results ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE